Nuveen Mortgage and Income Fund
Change company Symbol lookup
Select an option...
JLS Nuveen Mortgage and Income Fund
JNJ Johnson & Johnson
QIAN Qiansui International Group Co Ltd
BV Brightview Holdings Inc
PFE Pfizer Inc
MP Mp Materials Corp
WFG West Fraser Timber Co Ltd
MDT Medtronic PLC
ATMR^ Altimar Acquisition Corp II
AEG Aegon NV
Go

Company profile

Nuveen Mortgage and Income Fund (the Fund), formerly Nuveen Mortgage Opportunity Term Fund, is a non-diversified, closed-end management investment company. The Fund's investment objective is to generate attractive total returns through opportunistic investments in mortgage-backed security (MBS). It seeks to achieve its investment objective by investing primarily in non-agency residential MBS and commercial MBS. The Fund may also invest up to 20% of its managed assets in other permitted investments, including cash and cash equivalents, the United States treasury securities, non-mortgage related asset-backed securities, inverse floating rate securities, municipal securities, interest rate futures, interest rate swaps and swaptions, non-MBS credit default swaps and other synthetic mortgage-related exposure, including equity investments in mortgage real estate investment trusts (REITs). The Fund's investment advisor is Nuveen Fund Advisors, LLC.

Closing Price
$21.02
Day's Change
-0.0666 (-0.32%)
Bid
--
Ask
--
B/A Size
--
Day's High
21.10
Day's Low
21.01
Volume
(Heavy Day)
Volume:
13,970

10-day average volume:
8,258
13,970

Selective Serotonin Reuptake Inhibitors (SSRIs) Market- AbbVie Inc., Apotex Inc., Aurobindo Pharma Ltd., among others to contribute to the market growth|Industry Analysis, Market Trends, Opportunities and Forecast 2025

10:30 pm ET April 1, 2021 (PR Newswire) Print

https://mma.prnewswire.com/media/1477535/Technavio___SSRIs_market.jpg

The selective serotonin reuptake inhibitors (SSRIs) market is poised to grow by $ 809.73 mn during 2021-2025, progressing at a CAGR of about 4% during the forecast period.

View Exclusive report talking about Market scenarios, Estimates, the impact of lockdown, and Customer Behaviour.

Download FREE Sample Report !

The report on the selective serotonin reuptake inhibitors (SSRIs) market provides a holistic update, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis.

The report offers an up-to-date analysis regarding the current global market scenario and the overall market environment. The market is driven by rising prevalence of mental illnesses. With an increase in mental illnesses, there is a rising need for effective neurological drugs. Among the various neurological drugs available in the market, SSRIs drugs have high therapeutic efficacy.

The selective serotonin reuptake inhibitors (SSRIs) market analysis includes application segment and geography landscape. This study identifies the growing geriatric population as one of the prime reasons driving the selective serotonin reuptake inhibitors (SSRIs) market growth during the next few years. The rising awareness of depression among the geriatric population and the healthcare providers and the increasing availability of SSRI treatment regimes for such patients are supporting the growth of the market.

This report presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters.

The selective serotonin reuptake inhibitors (SSRIs) market covers the following areas: Selective Serotonin Reuptake Inhibitors (SSRIs) Market SizingSelective Serotonin Reuptake Inhibitors (SSRIs) Market ForecastSelective Serotonin Reuptake Inhibitors (SSRIs) Market AnalysisCompanies Mentioned

-- AbbVie Inc.

-- Apotex Inc.

-- Aurobindo Pharma Ltd.

-- Cipla Inc.

-- Eli Lilly and Co.

-- GlaxoSmithKline Plc

-- H. Lundbeck AS

-- Lupin Ltd.

-- Pfizer Inc.

-- Takeda Pharmaceutical Co. Ltd.

Related Reports on Health Care Include:

-- Endoscopic Closure Devices Market by Product and Geography - Forecast and Analysis 2021-2025- The endoscopic closure devices market size has the potential to grow by USD 579.00 million during 2021-2025, and the market's growth momentum will accelerate at a CAGR of 6.88%. Get FREE sample report in minutes

-- Marine Pharmaceuticals Market by Product, Source, and Geography - Forecast and Analysis 2021-2025- The marine pharmaceuticals market size has the potential to grow by USD 1.43 billion during 2021-2025, and the market's growth momentum will accelerate at a CAGR of 7.60%. Get FREE sample report in minutes

Key Topics Covered: Executive Summary

Market Landscape

-- Market ecosystem

-- Value chain analysis

Market Sizing

-- Market definition

-- Market segment analysis

-- Market size 2020

-- Market outlook: Forecast for 2020 - 2025

Five Forces Analysis

-- Five forces summary

-- Bargaining power of buyers

-- Bargaining power of suppliers

-- Threat of new entrants

-- Threat of substitutes

-- Threat of rivalry

-- Market condition

Market Segmentation by Application

-- Market segments

-- Comparison by Application

-- Depression - Market size and forecast 2020-2025

-- Anxiety and panic disorder - Market size and forecast 2020-2025

-- Other mental conditions - Market size and forecast 2020-2025

-- Market opportunity by Application

Customer landscape

Geographic Landscape

-- Geographic segmentation

-- Geographic comparison

-- North America - Market size and forecast 2020-2025

-- Europe - Market size and forecast 2020-2025

-- Asia - Market size and forecast 2020-2025

-- ROW - Market size and forecast 2020-2025

-- Key leading countries

-- Market opportunity by geography

-- Market drivers

-- Market challenges

-- Market trends

Vendor Landscape

-- Overview

-- Vendor landscape

-- Landscape disruption

Vendor Analysis

-- Vendors covered

-- Market positioning of vendors

-- AbbVie Inc.

-- Apotex Inc.

-- Aurobindo Pharma Ltd.

-- Cipla Inc.

-- Eli Lilly and Co.

-- GlaxoSmithKline Plc

-- H. Lundbeck AS

-- Lupin Ltd.

-- Pfizer Inc.

-- Takeda Pharmaceutical Co. Ltd.

Appendix

-- Scope of the report

-- Currency conversion rates for US$

-- Research methodology

-- List of abbreviations

About UsTechnavio is a leading global technology research and advisory company. Their research and analysis focuses on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions. With over 500 specialized analysts, Technavio's report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio's comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.

ContactTechnavio ResearchJesse MaidaMedia & Marketing ExecutiveUS: +1 844 364 1100UK: +44 203 893 3200Email: media@technavio.comWebsite: www.technavio.com/Report Link: Get FREE Sample Report in Minutes!

https://mma.prnewswire.com/media/1441766/Technavio_Logo.jpg

https://c212.net/c/img/favicon.png?sn=CG26807&sd=2021-04-01

View original content to download multimedia:http://www.prnewswire.com/news-releases/selective-serotonin-reuptake-inhibitors-ssris-market--abbvie-inc-apotex-inc-aurobindo-pharma-ltd-among-others-to-contribute-to-the-market-growthindustry-analysis-market-trends-opportunities-and-forecast-2025-301259378.html

SOURCE Technavio

https://rt.prnewswire.com/rt.gif?NewsItemId=CG26807&Transmission_Id=202104012230PR_NEWS_USPR_____CG26807&DateId=20210401

comtex tracking

Earnings Calendar and Events Data provided by |Terms of Use| © 2021 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., , and

Copyright © 2021. All rights reserved.